The Development of Vemurafenib for BRAF-mutated, Metastatic Melanoma

被引：0
|
作者：
Borellini, F. [1 ]
机构：
[1] Roche, Global Prod Strategy, San Francisco, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70545-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [1] The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma
    Kim, Alex
    Cohen, Mark S.
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2016, 11 (09) : 907 - 916
  • [2] Vemurafenib and cobimetinib in BRAF-mutated melanoma
    Rahman, Ahmadur
    [J]. LANCET ONCOLOGY, 2014, 15 (12): : E535 - E535
  • [3] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
    Larkin, James
    Ascierto, Paolo A.
    Dreno, Brigitte
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Sovak, Mika A.
    Chang, Ilsung
    Choong, Nicholas
    Hack, Stephen P.
    McArthur, Grant A.
    Ribas, Antoni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20): : 1867 - 1876
  • [4] Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients
    Nijenhuis, C. M.
    Huitema, A. D. R.
    Blank, C.
    Haanen, J. B. A. G.
    van Thienen, J. V.
    Rosing, H.
    Schellens, J. H. M.
    Beijnen, J. H.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (01): : 125 - 128
  • [5] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
    Ryan J. Sullivan
    Omid Hamid
    Rene Gonzalez
    Jeffrey R. Infante
    Manish R. Patel
    F. Stephen Hodi
    Karl D. Lewis
    Hussein A. Tawbi
    Genevive Hernandez
    Matthew J. Wongchenko
    YiMeng Chang
    Louise Roberts
    Marcus Ballinger
    Yibing Yan
    Edward Cha
    Patrick Hwu
    [J]. Nature Medicine, 2019, 25 : 929 - 935
  • [6] Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
    Sullivan, Ryan J.
    Hamid, Omid
    Gonzalez, Rene
    Infante, Jeffrey R.
    Patel, Manish R.
    Hodi, F. Stephen
    Lewis, Karl D.
    Tawbi, Hussein A.
    Hernandez, Genevive
    Wongchenko, Matthew J.
    Chang, YiMeng
    Roberts, Louise
    Ballinger, Marcus
    Yan, Yibing
    Cha, Edward
    Hwu, Patrick
    [J]. NATURE MEDICINE, 2019, 25 (06) : 929 - +
  • [7] Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
    del Carmen Alamo, Ma
    Ochenduszko, Sebastian
    Crespo, Guillermo
    Corral, Monica
    Oramas, Juana
    Sancho, Pilar
    Medina, Javier
    Garicano, Fernando
    Lopez, Pedro
    Campos Balea, Begona
    Rodriguez Garzotto, Analia
    Munoz-Couselo, Eva
    [J]. ONCOTARGETS AND THERAPY, 2021, 14 : 5345 - 5352
  • [8] Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
    Spagnolo, Francesco
    Ghiorzo, Paola
    Queirolo, Paola
    [J]. ONCOTARGET, 2014, 5 (21) : 10206 - 10221
  • [9] Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
    Amin, Asim
    Lawson, David H.
    Salama, April K. S.
    Koon, Henry B.
    Guthrie, Troy, Jr.
    Thomas, Sajeve S.
    O'Day, Steven J.
    Shaheen, Montaser F.
    Zhang, Bin
    Francis, Stephen
    Hodi, F. Stephen
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [10] Development of encorafenib for BRAF-mutated advanced melanoma
    Koelblinger, Peter
    Thuerigen, Olaf
    Dummer, Reinhard
    [J]. CURRENT OPINION IN ONCOLOGY, 2018, 30 (02) : 125 - 133
12345